Helicon Peptides: Degrading Active AR to Overcome Prostate Cancer Resistance

/in /by

Current AR therapies like enzalutamide target the inactive, unliganded AR conformation (AROFF) by binding its androgen pocket, preventing activation but leaving already active, agonist-bound AR (ARON), the real driver of tumor transcription and proliferation, untouched. This allows resistant tumors to adapt through AR gene amplification, mutations in the ligand-binding domain, or alternative activation pathways, leading […]

Read more

AM109: A PSMA‑Targeted CD137 Bispecific Antibody for Metastatic Castration‑Resistant Prostate Cancer (mCRPC / mAPMR)

/in , /by

AM109 is designed as a bispecific agent that links a PSMA‑targeting humanized antibody to a CD137 (4‑1BB)‑targeting affibody, effectively creating a molecular bridge between prostate cancer cells and T cells in the tumor microenvironment. The rationale is straightforward: by restricting CD137 activation to sites where PSMA is expressed, the therapy aims to drive potent anti‑tumor […]

Read more

A nano-PROTAC on the horizon: combining targeted protein degradation and ferroptosis for advanced prostate cancer

/in , /by

A new study from Wuhan University and the Renmin Hospital of Wuhan University has reported a promising preclinical strategy for advanced prostate cancer, especially castration-resistant prostate cancer (CRPC). The work was published online in Angewandte Chemie International Edition, one of the leading international journals in chemistry. The study describes a new nano-PROTAC platform designed to […]

Read more

A New Drug Candidate TB511 Shows Promise for Hard-to-Treat Prostate Cancer

/in , /by

Castration-resistant prostate cancer (aka androgen pathway modulation resistant prostate cancer, APMR) is one of the toughest forms of prostate cancer to treat. It becomes resistant to hormone therapy, and current immunotherapies don’t work well on it. The main reason is that CRPC tumors create an immune-“cold” environment filled with M2 macrophages, a type of immune […]

Read more

HY809382: PRC2 Degrader Which Works With EZH2 Inhibitors Resistant Prostate Cancer

/in /by

Prostate cancer becomes especially hard to treat when it turns resistant to hormone therapies like enzalutamide, largely because of a protein complex called PRC2 that shuts down genes needed to fight tumors. PRC2’s key parts, EZH2 and EED, fuel cancer growth, immune evasion, and drug resistance in prostate tumors, as well as others like endometrial […]

Read more

QL535: CD2-Based PSMA T-Cell Engager Maintains Anti-Tumor Activity in Advanced Prostate Cancer Models

/in , /by

PSMA-targeted T-cell engagers have struggled in solid tumors because they don’t activate T cells strongly enough and the immune cells become exhausted quickly. QL535 solves this problem by adding a second co-stimulatory signal through CD2, a molecule on T cells that’s abundant in prostate cancer tumors. Researchers analyzed immune cells from 14 advanced prostate cancer […]

Read more

MMAE-Based LIV1 ADC Achieves Sustained Tumor Control in Prostate Cancer Models

/in , /by

LIV1, a zinc transporter protein, sits on the surface of 72% of prostate tumors with minimal expression in healthy tissues. This makes it an ideal target for antibody-drug conjugates, a therapeutic class combining antibody specificity with potent cytotoxic payloads. Researchers developed 48D6, a humanized anti-LIV1 monoclonal antibody with substantially improved pharmacokinetics compared to previous versions. […]

Read more

QLS2401: A Trispecific PSMA/STEAP1/CD3 T‑Cell Engager for mCRPC

/in , /by

QLS2401 is a trispecific T‑cell engager designed for metastatic castration‑resistant prostate cancer (mCRPC). It binds three targets at once: PSMA and STEAP1 on tumor cells, plus CD3 on T cells. This design allows it to physically connect a patient’s T cells to prostate‑cancer cells, triggering T‑cell activation and killing of the tumor. Both PSMA and […]

Read more

Antibody MQI‑201: Turning Cold Tumors Hot in Advanced Cancer

/in /by

A new antibody called MQI‑201 is being developed as a potential treatment for advanced solid cancers that respond poorly to existing immunotherapies, such as certain types of prostate cancer, pancreatic cancer, and sarcomas. These tumors are often called “cold” because they have little immune cell infiltration and usually do not benefit from checkpoint inhibitors or […]

Read more

Bvax in Prostate Cancer: A B‑Cell Therapy That Penetrates Immune‑Excluded Tumors

/in , /by

A new type of cancer treatment called Bvax is drawing attention in prostate cancer because it may be able to reach inside tumors that are hard to treat with standard immunotherapies. Bvax is made from a patient’s own B cells, which are activated and loaded with tumor‑related proteins, then given back to the body. Once […]

Read more